Clinical trial
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
NCT00128531 · GP-Pharm, Industry · Completed
Key facts
| NCT number | NCT00128531 |
|---|---|
| Title | Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer |
| Official title | Efficacy and Safety of a New Leuprolide Acetate 3.75 mg Depot Formulation, GP-Pharm S.A., When Given as Palliative Treatment to Prostate Cancer Patients |
| Lead sponsor | GP-Pharm, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | leuprolide acetate |
| Enrollment | 120 |
| Start date | Sep 1, 2005 |
| Completion | Nov 1, 2007 |
| First posted | Aug 10, 2005 |
| Last update posted | Nov 14, 2007 |
| Countries | Austria, Czechia, Germany, Hungary, Italy, Slovakia, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: